Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition, today announced the U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix (amino acids in dextrose) Injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) Injections. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.,2 making it easier to reach pa

 Baxter Announces U.S. FDA Approval of Clinimix and Clinimix E with Higher Protein for Patients Requiring Parenteral Nutrition

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc.

Baxter Announces Exclusive Distribution Agreement With bioMérieux for Novel Acute Kidney Injury Diagnostic Test in Europe and U.S.

Baxter to Host Third-Quarter 2020 Financial Results Conference Call for Investors

The Baxter International Inc. (NYSE:BAX) share price dropped recently. But is it enough of a pullback to justify the interest of investors?

Baxter International: A Health Care Stock With an 89-Year History

Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.

Baxter (BAX) Attains FDA De Novo Authorization for Theranova

Baxter Announces U.S. FDA De Novo Authorization for Theranova Dialyzers Enabling HDx Therapy

Baxter (BAX) reported earnings 30 days ago. What's next for the stock?

How Has BAX Performed 30 Days Post Earnings

Bullish On Baxter: Cruising Along, Business As Usual; $90 Price Target Set

Baxter to Present at the Virtual Morgan Stanley 18th Annual Global Healthcare Conference

Baxter to Present at the 2020 Wells Fargo Virtual Healthcare Conference

Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.

Baxter (BAX) Receives EUA for Regiocit Replacement Solution

Baxter Obtains U.S. FDA Emergency Use Authorization for Regiocit Replacement Solution Used in CRRT

Baxter Obtains U.S. FDA Emergency Use Authorizations for HF20 Set and ST Set Used in CRRT During Covid-19 Pandemic

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International, Inc.

Baxter Introduces Virtual Peritoneal Dialysis Excellence Academy for Nurses in the U.S.

Baxter International's (BAX) CEO Joe Almeida on Q2 2020 Results - Earnings Call Transcript

Baxter's (BAX) second-quarter earnings reflect weak performance across Medication Delivery, Pharmaceutical and Advanced Surgery business units and contraction in margins.

Baxter (BAX) Earnings and Revenues Miss Estimates in Q2

Baxter Reports Second-Quarter 2020 Results

Bio-Rad Laboratories

QuidelOrtho Corp

Stryker

Teleflex

Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.

Medical Products Stock Earnings on Jul 30: BAX, SYK & More

DEERFIELD, Ill. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Baxter International Inc.

Baxter and Ayogo Announce Partnership for Unique Digital Health Solutions for Home Dialysis

Abbott Labs

Boston Scientific

Edwards Lifesciences

Globus Medical

Johnson & Johnson

Medtronic

NuVasive

Health care is supposed to be a very defensive sector in investing. After all, diseases and conditions such as cancer, diabetes, heart disease, kidney failure, dementia, joint damage and spinal issues are just a small percentage of the ailments that have to be routinely treated.

Beyond COVID-19, Credit Suisse Shows Its Top Health Care Recovery Stock Picks

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced today it has been named a top-scoring company on the 2020 Disability Equality Index® (DEI) by Disability:IN, the leading nonprofit resource for business disability inclusion worldwide. The company’s 90% score places it in the top 10% of all companies in the index and earns the “Best Place to Work for Disability Inclusion” recognition. The DEI ranks companies across six ca

Baxter Ranks in Top 10% on 2020 Disability Equality Index

Baxter (BAX) receives FDA approval for Altapore Shape that will provide surgeons versatile options to advance the art of healing and boost clinical outcomes during a surgery.

Baxter Gets FDA Nod for Altapore Shape Bioactive Bone Graft

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2020 financial results on Thursday, July 30, 2020, at 7:30 a.m. Central Time. To access the call, dial (844) 471-1702 (domestic) or (574) 990-3603 (international). Please dial into the call at least ten minutes prior to the start for the operator to connect you. The Conference ID is 2386827. This call is also being webcast a

Baxter to Host Second-Quarter 2020 Financial Results Conference Call for Investors

Hill-Rom Hlds

Intuitive Surgical

Perrigo

ResMed

Zimmer Biomet Hlds

Medical Products Industry's Near-Term Outlook Lacks Spark

American Tower

American Water Works

Cardinal Health

Chubb

Cogent Communications Holdings

Costco

Expeditors International of Washington

Microchip Technology

Nasdaq

Newmont Mining

Northrop Grumman

PepsiCo

PetMed Express

Procter & Gamble

Pool

Power Integrations

Xilinx

These 21 stocks were doling out dividend increases as the coronavirus crisis accelerated – and as many stocks were cutting or outright suspending their payouts.

21 Dividend Increases Announced During the COVID Crisis

News for Baxter Stock (BAX)